Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics Inc. announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel for the treatment of Duchenne muscular dystrophy (DMD). The randomized, double-blind, placebo-controlled study met both its primary endpoint, measuring skeletal function by PUL v2.0, and a key secondary cardiac endpoint, left ventricular ejection fraction (LVEF), achieving statistical significance with p-values of 0.03 and 0.04, respectively. Statistical significance was also achieved in all type 1 error controlled secondary endpoints. The safety and tolerability profile of Deramiocel remained favorable and consistent with previous clinical experience. These results have already been presented by the company, and Capricor plans to submit its response to a Complete Response Letter from the FDA, incorporating the HOPE-3 data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-117947), on December 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.